0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RegeneRx Biopharmaceuticals
Its shares trade under the ticker RGRX. It has been listed since 23 December 1986. In the fiscal year to 31 December 2022, it reported revenue of $76,761 and a net loss of $1.7m. At that date it held total assets of $382,177 and shareholders' equity of −$3.4m.
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The company is headquartered in Rockville, Maryland. The firm is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The firm's segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The firm has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Dec 1986
- Employees
- 3
- Website
- regenerx.com ↗
Leadership
Pay as last reported
- Dr. Allan GoldsteinChairman of the Board, Founder, Chief Scientific Officer, since 1982$156,539
- Mr. J. FinkelsteinPresident, Chief Executive Officer, Director, since 1984$165,262
- Dr. Alessandro NosedaDirector$33,637
- Mr. Mauro BoveIndependent Director$33,637
- Mr. Raymond ElseyIndependent Director$40,644
- Mr. Joseph McnayIndependent Director$40,644
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Thymosin beta 4 is a synthetic copy of a naturally occurring peptide isolated from bovine thymus glands.
- RGN-259 is a preservative-free eye drop formulation for tissue repair.
- RGN-352 is an injectable formulation targeting cardiovascular and nervous system diseases.
Weaknesses
- The company employs only 3 full-time employees in Rockville, Maryland.
- RegeneRx has no products approved for market use as of now.
- RGN-137 is a topical gel for dermal wounds but not yet approved.
Opportunities
- RGN-259 eye drops could address unmet needs in ophthalmic treatments.
- RGN-352 injectable formulation may expand into cardiovascular disease markets.
- RGN-137 gel could target scar reduction in wound care markets.
Threats
- RegeneRx faces competition from other biotechnology firms in the Health Care sector.
- The company's small size with only 3 employees may limit research capabilities.
- RGN-259, RGN-352, and RGN-137 are still in clinical development without market approval.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.